Skip to main content

Saniona invites investors to participate in a conference call and webcast presentation regarding its recent $65 million financing

Written by Customer Service on . Posted in Public Companies.

PRESS RELEASE12 August 2020Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced a conference call and webcast presentation regarding its recent directed share issue generating gross proceeds of USD 65 million (approximately SEK 567 million).The event will take place on Friday August 14th at 2 p.m. CET and will feature a presentation by Saniona’s management team to discuss the strategy and rationale for the financing, as well as an update on Saniona’s advancement of its late-stage clinical trials with Tesomet in two rare eating disorders, hypothalamic obesity (HO) and Prader Willi Syndrome (PWS), as well as progress building its U.S.-based organization in support of these programs.VIDEO DETAILShttps://abgsc.webex.com/abgsc/onstage/g.php?MTID=e7fd1a20a6a1661b83500532c896d7dd0Event number: 137 140 9570Please add your questions in the Q&A field during the presentation.If you prefer not to download the Webex app, please use the link temporary application to join the event.AUDIO DETAILSUS: +1 408 758 98 56 Global call-in numbersEvent number: 137 140 9570For those who are unable to listen at this time, a replay of the call will be available after the event through the investor section of Saniona’s web site at https://saniona.com/investors/company-presentations/.For more information, please contactRami Levin, President & CEO, SanionaMobile: +1 (781) 987 3144E-mail: rami.levin@saniona.comThe information was submitted for publication, through the agency of the contact person set out above, at 08:00 a.m. CET on August 12, 2020.About SanionaSaniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system. The company has four programs in clinical development. Saniona intends to develop and commercialize treatments for rare disease indications such as hypothalamic obesity and Prader-Willi syndrome on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona also has out-licensing agreements with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, and in Boston, US. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.Attachment20200812 – PR – Financing call – UK

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.